Istradefylline Effect Protocol on Parkinson's Disease Tremor
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory
pilot study, the investigator intends to enroll a pilot sample of 25 patients with
Parkinson's disease who are being started on the novel FDA approved medication
"Istradefylline'' as an add on therapy for management of their motor symptoms (based on the
judgment of the movement disorders specialist, if patients are in sub-optimal management of
their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator
will evaluate their motor symptoms before starting the new medication, including their
MDS-UPDRS total and MDS-UPDRS-III scores.